RPL31A Antibody

What is RPL31 and why is it significant in research?

RPL31 (Ribosomal Protein L31) is a component of the 60S large ribosomal subunit involved in protein synthesis within cells. It functions as part of the large ribonucleoprotein complex responsible for cellular protein synthesis . Beyond its canonical role in translation, RPL31 has gained significance in cancer research as it has been found to be overexpressed in certain cancers, notably prostate carcinoma compared to benign prostate tissues . Studies have demonstrated that RPL31 influences cell proliferation and cell-cycle progression, making it a potential target for understanding cancer biology and developing therapeutic strategies .

What applications are RPL31 antibodies validated for?

RPL31 antibodies have been validated for multiple research applications with varying degrees of optimization. The most commonly validated applications include:

It's important to note that optimal dilutions may be sample-dependent, and researchers should perform antibody titration experiments to determine the best conditions for their specific experimental system .

How can I verify the specificity of an RPL31 antibody for my research?

To verify the specificity of an RPL31 antibody, implement a multi-tiered validation approach. Begin with Western blot analysis using lysates from cells known to express RPL31 (such as HepG2, HEK-293T, or HeLa) and look for a single band at approximately 14 kDa, which is the predicted molecular weight of RPL31 . Compare results with a positive control and include a negative control using siRNA-mediated knockdown of RPL31 to confirm specificity . Cross-validate results across multiple applications like immunofluorescence to ensure consistent staining patterns. When evaluating specificity across species, consider the homology between human, mouse, and rat RPL31, as most commercial antibodies show reactivity with samples from these species . Finally, verify that the observed staining pattern aligns with the known subcellular localization of RPL31, primarily in ribosomes and the nucleolus.

How does RPL31 knockdown affect cell-cycle progression and what controls should I include?

RPL31 knockdown significantly impacts cell-cycle progression, with research demonstrating it increases the proportion of cells in G0/G1 phase while decreasing the proportion in S phase . When designing RPL31 knockdown experiments, implement the following controls and considerations:

• Knockdown efficiency verification: Use quantitative RT-PCR to confirm at least 70-80% reduction in RPL31 mRNA levels.

• Multiple siRNA controls: Include at least two different siRNA sequences targeting RPL31 to rule out off-target effects.

• Appropriate control siRNA: Use non-targeting siRNA (e.g., siLuc as used in published studies) rather than scrambled sequences .

• Time-course analysis: Analyze cell cycle at multiple time points (24h, 48h, 72h) after knockdown to capture dynamic changes.

• Complementary methods: Combine FACS analysis with BrdU incorporation and expression analysis of cell cycle markers.

The experimental design should include analysis of downstream mediators including p53, p21, and MDM2, as RPL31 knockdown has been shown to increase these proteins' expression levels . For proper interpretation, quantify cell cycle distribution data using software like CellQuest and present as mean ± standard deviation with appropriate statistical analysis (p-values <0.05 and <0.01 for significance) .

What is the relationship between RPL31 and the p53 pathway in cancer research?

The relationship between RPL31 and the p53 pathway represents a significant research area with implications for cancer biology. Studies have revealed that RPL31 knockdown leads to increased protein levels of tumor suppressor p53 and its downstream targets, p21 (a cell-cycle negative regulator) and MDM2 (an E3 ubiquitin ligase targeting p53) . This relationship manifests through several mechanisms:

• p53 protein stabilization: RPL31 silencing decreases p53 degradation rates, as demonstrated through cycloheximide chase experiments that showed prolonged p53 half-life in RPL31-knockdown cells .

• Feedback regulation: The increased MDM2 expression observed after RPL31 knockdown likely represents the canonical p53-MDM2 feedback loop, where p53 activates MDM2 transcription .

• Cell cycle impact: The G0/G1 arrest observed after RPL31 knockdown appears partially p53-dependent, as co-silencing of p53 partially rescues the cell cycle defects .

When investigating this relationship, researchers should employ dual knockdown experiments (RPL31 + p53) to establish causality and examine changes in cell proliferation, cell cycle distribution, and expression of p53 target genes. Western blot analysis should track protein stabilization over time with quantitative densitometry normalized to loading controls like β-actin .

How can I investigate RPL31's role in therapeutic resistance in cancer models?

To investigate RPL31's role in therapeutic resistance, particularly in models like bicalutamide-resistant prostate cancer cells, implement a multi-faceted experimental approach:

• Expression profiling: Compare RPL31 mRNA and protein expression between therapy-sensitive and therapy-resistant cell lines. Research has shown that RPL31 mRNA is more abundantly expressed in bicalutamide-resistant LNCaP (BicR) cells compared to parental LNCaP cells .

• Functional knockdown studies: Use siRNA-mediated knockdown of RPL31 in resistant cells and assess changes in:

  • Proliferation rates (cell counting, MTT/XTT assays)

  • Cell cycle progression (FACS analysis)

  • Apoptotic markers (Annexin V staining)

  • Drug sensitivity (dose-response curves)

• Overexpression models: Generate stable cell lines overexpressing RPL31 (as done with LNCaP-RPL31 #39 and #63 clones) and assess if this confers resistance to therapeutic agents .

• Downstream pathway analysis: Examine changes in p53, p21, and MDM2 expression in response to both RPL31 manipulation and drug treatment .

• In vivo validation: Consider xenograft models using RPL31-manipulated cells to validate findings in a more physiologically relevant context.

The experimental design should include appropriate technical and biological replicates, time-course analyses, and combination treatments to thoroughly assess RPL31's contribution to the resistant phenotype .

What are the optimal conditions for detecting RPL31 by Western blot?

For optimal detection of RPL31 by Western blot, implement the following methodological considerations:

• Gel selection: Use 15% SDS-PAGE gels due to RPL31's low molecular weight (predicted size of 14 kDa) .

• Sample preparation: Extract total protein from cells using standard lysis buffers containing protease inhibitors. Load 30 μg of protein per lane as used in published protocols .

• Transfer conditions: Use optimized transfer conditions for small proteins (higher methanol concentration, shorter transfer time) to prevent loss of small proteins.

• Blocking conditions: Block membranes with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature.

• Antibody dilution: Use a 1:500 to 1:1000 dilution of primary RPL31 antibody . Incubate overnight at 4°C for optimal results.

• Positive controls: Include lysates from validated cell lines such as HepG2, HeLa, or HEK-293T, known to express RPL31 .

• Detection system: Both chemiluminescence and fluorescence-based detection systems are suitable, with the latter offering better quantification capabilities.

When troubleshooting, common issues include absence of signal (which may require increased protein loading or decreased antibody dilution) and non-specific bands (which may require more stringent washing or increased blocking) .

How can I optimize immunofluorescence protocols for RPL31 detection?

To optimize immunofluorescence protocols for RPL31 detection, consider these methodological approaches:

• Fixation method: Compare paraformaldehyde (4%, 10-15 minutes) with methanol fixation (100%, -20°C, 10 minutes) to determine which best preserves RPL31 epitopes while maintaining cellular morphology.

• Permeabilization: Use 0.1-0.5% Triton X-100 for 5-10 minutes; adjust concentration based on cell type.

• Antibody dilution range: Start with 1:50-1:500 dilutions and perform a titration experiment to determine optimal signal-to-noise ratio.

• Incubation conditions: Compare room temperature (1-2 hours) versus 4°C (overnight) incubation for primary antibody.

• Signal amplification: Consider using biotin-streptavidin systems for weak signals, especially in tissues with low expression.

• Counterstaining: Include DAPI for nuclear visualization and reference for RPL31's nucleolar localization.

• Colocalization studies: Use markers for nucleoli (fibrillarin) or ribosomes (RPS6) to confirm expected localization patterns.

• Controls: Include a negative control (primary antibody omission), positive control (known expressing cells like HepG2), and siRNA knockdown control to validate specificity .

Document optimization parameters systematically in a laboratory notebook, including images at each condition tested, to establish a reproducible protocol for future experiments.

What approaches can address cross-reactivity issues with RPL31 antibodies?

When encountering cross-reactivity issues with RPL31 antibodies, implement these systematic troubleshooting approaches:

• Antibody selection: Choose antibodies targeting unique regions of RPL31 rather than highly conserved ribosomal domains that may cross-react with other ribosomal proteins.

• Validation through knockdown: Perform RPL31 siRNA knockdown experiments to confirm the specificity of bands in Western blot or staining patterns in immunofluorescence .

• Peptide competition: Pre-incubate the antibody with excess immunizing peptide to block specific binding sites before application to samples.

• Increased washing stringency: Implement more stringent washing conditions (higher salt concentration or mild detergents) to reduce non-specific binding.

• Blocking optimization: Test different blocking agents (BSA, normal serum, commercial blockers) to reduce background.

• Secondary antibody controls: Include a secondary-only control to identify potential non-specific binding from the secondary antibody.

• Species verification: Confirm the species reactivity of the antibody matches your experimental model. Available data indicates cross-reactivity with human, mouse, and rat samples for many commercial RPL31 antibodies .

• Alternative antibody sources: Compare antibodies from different vendors or different clones/lots from the same vendor to identify the most specific option for your application.

Document all optimization steps systematically to establish a robust protocol that minimizes cross-reactivity while maintaining specific detection of RPL31.

How can I utilize RPL31 antibodies for studying cancer biomarkers?

To utilize RPL31 antibodies for cancer biomarker research, implement a comprehensive strategy combining multiple techniques:

• Tissue microarray (TMA) analysis: Apply RPL31 antibodies to TMAs containing various cancer types and matched normal tissues to assess expression patterns across multiple samples simultaneously. Clinical data indicates RPL31 is overexpressed in prostate carcinomas compared to benign prostate tissues by >2-fold .

• Correlation with clinical data: Analyze RPL31 expression in relation to:

  • Tumor grade and stage

  • Therapy response (particularly in hormone-resistant cancers)

  • Patient survival outcomes

  • Other established biomarkers

• Multi-marker panels: Combine RPL31 with other markers to develop more specific and sensitive diagnostic or prognostic panels.

• Automated image analysis: Employ digital pathology tools to quantify RPL31 staining intensity and distribution objectively.

• Liquid biopsy applications: Investigate RPL31 protein levels in circulating tumor cells or exosomes as potential non-invasive biomarkers.

• Functional validation: Complement expression data with functional studies (knockdown/overexpression) to establish biological relevance of RPL31 in cancer progression .

• Translational relevance: Assess whether RPL31 expression correlates with response to specific therapies, particularly in therapy-resistant contexts like bicalutamide-resistant prostate cancer .

This approach should be validated across multiple independent cohorts and compared with established cancer biomarkers to determine RPL31's clinical utility.

What are the considerations for using RPL31 antibodies in co-immunoprecipitation studies?

When designing co-immunoprecipitation (Co-IP) experiments with RPL31 antibodies to identify protein-protein interactions, consider these advanced methodological aspects:

• Antibody selection criteria: Choose antibodies that recognize native (non-denatured) RPL31 epitopes, as many commercially available antibodies are raised against denatured proteins. Test multiple antibodies to identify those that efficiently immunoprecipitate the native protein.

• Crosslinking optimization: Implement reversible crosslinking (such as DSP or formaldehyde) to stabilize transient protein interactions, particularly when investigating RPL31's interactions with p53 or MDM2 . Optimize crosslinking time and concentration to balance between stabilizing interactions and maintaining antibody epitope accessibility.

• Lysis conditions: Use gentle lysis buffers (containing 0.5-1% NP-40 or Triton X-100) to preserve protein complexes. Consider specialized ribosome isolation buffers when investigating RPL31's interactions within the ribosomal complex.

• Controls: Include multiple controls:

  • IgG-matched negative control

  • Input sample (5-10% of lysate)

  • Reverse Co-IP (immunoprecipitate with antibodies against suspected interacting partners)

  • RPL31-depleted lysate as specificity control

• RNase treatment: Include RNase treatment controls to distinguish between direct protein-protein interactions and RNA-mediated associations, particularly important for ribosomal proteins.

• Elution strategy: Compare different elution methods (SDS, competitive peptide elution, acidic glycine) to maximize recovery while minimizing antibody contamination.

• Detection methods: Use sensitive detection methods (MS/MS, silver staining, or highly sensitive Western blot) for identification of low-abundance interacting partners.

The experimental design should address the complexities of studying ribosomal proteins, which exist in large complexes and may have extra-ribosomal functions .

How should I interpret conflicting data between RPL31 protein and mRNA expression in my samples?

When encountering discrepancies between RPL31 protein and mRNA expression levels, implement this systematic approach to interpretation and troubleshooting:

• Technical validation: First confirm the discrepancy is not due to technical issues:

  • Verify antibody specificity with appropriate controls

  • Validate RNA quality and primer efficiency for qPCR

  • Use multiple detection methods for both protein (Western blot, IF, IHC) and RNA (qRT-PCR, RNA-seq)

• Post-transcriptional regulation assessment: RPL31, like other ribosomal proteins, may undergo significant post-transcriptional regulation. Investigate:

  • microRNA targeting of RPL31 mRNA

  • RNA-binding protein interactions affecting translation

  • mRNA stability (perform actinomycin D chase experiments)

• Protein turnover analysis: Examine protein degradation rates using cycloheximide chase assays, as research shows RPL31 may influence p53 degradation , suggesting complex regulatory relationships with protein stability machinery.

• Subcellular localization: Check if the protein is sequestered in different cellular compartments, affecting extraction efficiency compared to mRNA detection.

• Feedback mechanisms: Investigate potential autoregulatory feedback loops where RPL31 protein levels might influence its own mRNA expression.

• Experimental timing considerations: Consider temporal dynamics - protein expression may lag behind mRNA changes, requiring time-course experiments.

• Biological context interpretation: In some contexts, particularly cancer, discrepancies between mRNA and protein may represent dysregulated translation or post-translational modifications with potential biological significance .

Document all troubleshooting steps systematically and consider the discrepancy itself as potentially informative data about RPL31 regulation in your experimental system.

How can RPL31 antibodies be utilized in studying ribosome heterogeneity?

Ribosome heterogeneity is an emerging research area where different ribosome populations with distinct compositions may serve specialized functions. To investigate RPL31's contribution to ribosome heterogeneity, implement these advanced methodological approaches:

• Ribosome profiling with RPL31 immunoprecipitation: Combine ribosome profiling with RPL31 immunoprecipitation to identify mRNAs specifically associated with RPL31-containing ribosomes versus those lacking RPL31.

• Polysome fractionation analysis: Use sucrose gradient centrifugation to separate different ribosomal populations, followed by Western blot analysis with RPL31 antibodies to determine its distribution across monosomes and polysomes.

• Proximity labeling approaches: Employ BioID or APEX2 fused to RPL31 to identify proteins in proximity to RPL31 within intact ribosomes in different cellular contexts or stress conditions.

• Quantitative proteomic analysis: Use SILAC or TMT labeling combined with mass spectrometry to compare the stoichiometry of RPL31 across different ribosome populations isolated from various tissues or cellular conditions.

• Single-molecule imaging: Implement super-resolution microscopy with fluorescently labeled RPL31 antibodies to visualize potential heterogeneity in ribosome composition at the single-molecule level.

• Disease model comparisons: Compare RPL31 incorporation into ribosomes between normal and disease states, particularly in cancer models where RPL31 has shown differential expression .

• Multi-omics integration: Correlate RPL31-associated ribosome populations with translatome and proteome data to identify functional consequences of RPL31 heterogeneity.

This research direction could reveal whether RPL31 contributes to specialized translation in cancer or other disease contexts, potentially explaining its role beyond canonical ribosome function .

What considerations are important when developing multiplex imaging protocols including RPL31?

For developing multiplex imaging protocols that include RPL31 antibodies alongside other markers, address these critical considerations:

• Antibody compatibility assessment: Systematically test antibody combinations to identify potential cross-reactivity:

  • Perform single-color controls for each antibody

  • Test antibody pairs in different orders to detect potential interference

  • Consider the species origin of antibodies to avoid cross-reactivity with secondary antibodies

• Epitope retrieval optimization: Different antigens may require different epitope retrieval methods. Test whether the optimal condition for RPL31 (likely citrate buffer, pH 6.0) is compatible with other target proteins.

• Fluorophore selection strategy: When selecting fluorophores:

  • Match fluorophore brightness with target abundance (brighter fluorophores for less abundant targets)

  • Consider RPL31's cellular localization (primarily nucleolar/cytoplasmic) when pairing with other markers

  • Minimize spectral overlap, particularly important when analyzing subcellular colocalization

• Sequential staining protocols: For highly multiplexed imaging:

  • Test cyclic immunofluorescence with antibody stripping between rounds

  • Validate that RPL31 epitopes remain stable through multiple rounds of stripping/restaining

  • Consider tyramide signal amplification for enhanced sensitivity

• Image acquisition parameters: Optimize for:

  • Z-stack depth to capture the full volume of RPL31 staining

  • Exposure settings that prevent saturation while maintaining sensitivity

  • Sequential channel acquisition to prevent bleed-through

• Quantification strategies: Develop analysis pipelines that account for:

  • Subcellular segmentation (nuclear, nucleolar, cytoplasmic)

  • Signal normalization across multiple markers

  • Colocalization metrics appropriate for ribosomal proteins

• Validation controls: Include biological controls known to express different levels of RPL31, such as cancer versus normal cells, or RPL31 knockdown samples .

Document optimization steps systematically to establish reproducible multiplex imaging protocols that accurately capture RPL31's expression and localization relative to other markers of interest.

How can I address inconsistent RPL31 antibody performance across different experimental batches?

To address batch-to-batch variability in RPL31 antibody performance, implement this systematic troubleshooting approach:

• Antibody storage and handling optimization:

  • Aliquot antibodies upon receipt to minimize freeze-thaw cycles

  • Store at recommended temperatures (-20°C or -80°C)

  • Track lot numbers and expiration dates meticulously

  • Consider adding preservatives like sodium azide (0.02%) to working solutions

• Standardization procedures:

  • Create a reference lysate batch from a cell line with stable RPL31 expression (e.g., HepG2)

  • Run this reference sample in each experiment as an internal control

  • Normalize experimental samples to this standard

  • Generate standard curves for quantification when possible

• Protocol consistency enforcement:

  • Develop detailed SOPs for sample preparation, including buffer compositions

  • Standardize protein quantification methods

  • Use consistent incubation times and temperatures

  • Implement automated systems where possible to reduce human variability

• Quality control testing:

  • Perform periodic validation using positive controls (HepG2, HEK-293T)

  • Include negative controls like RPL31 knockdown samples

  • Test new antibody lots against previous lots before implementing fully

• Data normalization strategies:

  • Normalize to multiple housekeeping proteins rather than a single loading control

  • Consider using total protein normalization methods (Ponceau S, REVERT total protein stain)

  • Implement appropriate statistical methods to account for batch effects

• Documentation system:

  • Maintain a detailed antibody performance database

  • Record all experimental parameters with each use

  • Note any deviations from standard protocols

By implementing these systematic approaches, researchers can minimize variability and ensure consistent, reproducible results across different experimental batches when using RPL31 antibodies.

What approach should I take when RPL31 antibody produces unexpected cellular localization patterns?

When RPL31 antibody produces unexpected localization patterns, implement this systematic troubleshooting and interpretation strategy:

• Validate antibody specificity:

  • Confirm specificity via RPL31 knockdown in immunofluorescence experiments

  • Test multiple antibodies targeting different epitopes of RPL31

  • Perform peptide competition assays to confirm binding specificity

• Assess biological conditions:

  • Evaluate whether unexpected localization may reflect biological reality rather than technical artifact

  • Research has shown ribosomal proteins can have extra-ribosomal functions and relocalize under stress conditions

  • Consider cell cycle phase, as RPL31 is involved in cell cycle regulation

• Optimize fixation methods:

  • Compare different fixation protocols (paraformaldehyde vs. methanol vs. acetone)

  • Test fixation durations (10 min vs. 20 min vs. 30 min)

  • Try different permeabilization reagents (Triton X-100 vs. saponin)

• Perform co-localization studies:

  • Co-stain with markers for expected locations (nucleolin for nucleoli, RPS6 for ribosomes)

  • Include markers for unexpected locations to confirm or refute localization

  • Use super-resolution microscopy for more precise localization

• Consider experimental conditions:

  • Test different cell densities, as contact inhibition may affect localization

  • Evaluate serum starvation or other stress conditions that might trigger relocalization

  • Check for mycoplasma contamination, which can cause aberrant staining patterns

• Cross-validate with other methods:

  • Perform subcellular fractionation followed by Western blot

  • Use GFP-tagged RPL31 expression to confirm localization in live cells

  • Consider proximity labeling methods (BioID, APEX) to validate interaction partners at unexpected locations

Document all findings systematically, as unexpected localization patterns might represent novel biological insights about RPL31 function beyond its canonical role in ribosomes .